[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

PA8469101A1 - Ligandos azabiciclicos de receptores 5ht1 - Google Patents

Ligandos azabiciclicos de receptores 5ht1

Info

Publication number
PA8469101A1
PA8469101A1 PA19998469101A PA8469101A PA8469101A1 PA 8469101 A1 PA8469101 A1 PA 8469101A1 PA 19998469101 A PA19998469101 A PA 19998469101A PA 8469101 A PA8469101 A PA 8469101A PA 8469101 A1 PA8469101 A1 PA 8469101A1
Authority
PA
Panama
Prior art keywords
azabiciclic
leagues
receivers
aminometilphenoximetil
benzoisoxazoles
Prior art date
Application number
PA19998469101A
Other languages
English (en)
Inventor
Gene Michael Bright
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of PA8469101A1 publication Critical patent/PA8469101A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Reproductive Health (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Addiction (AREA)
  • Urology & Nephrology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Luminescent Compositions (AREA)

Abstract

LA PRESENTE INVENCION SE REFIERE A NUEVOS COMPUESTOS AZABICICLICOS AMINOMETILFENOXIMETIL/BENZOISOXAZOL SUSTITUIDOS, A INTERMEDIOS PARA SU PREPARACION, A COMPOSICIONES FARMACEUTICAS QUE LOS CONTIENEN Y A SU USO EN MEDICINA.
PA19998469101A 1998-04-09 1999-03-17 Ligandos azabiciclicos de receptores 5ht1 PA8469101A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US8123798P 1998-04-09 1998-04-09

Publications (1)

Publication Number Publication Date
PA8469101A1 true PA8469101A1 (es) 2000-09-29

Family

ID=22162936

Family Applications (1)

Application Number Title Priority Date Filing Date
PA19998469101A PA8469101A1 (es) 1998-04-09 1999-03-17 Ligandos azabiciclicos de receptores 5ht1

Country Status (41)

Country Link
US (2) US6525048B1 (es)
EP (1) EP1070065B1 (es)
JP (1) JP3496759B2 (es)
KR (1) KR100378931B1 (es)
CN (1) CN1117092C (es)
AP (1) AP1175A (es)
AR (1) AR015751A1 (es)
AT (1) ATE248838T1 (es)
AU (1) AU749254B2 (es)
BG (1) BG104915A (es)
BR (1) BR9909522A (es)
CA (1) CA2327782A1 (es)
CO (1) CO5080727A1 (es)
CZ (1) CZ20003684A3 (es)
DE (1) DE69910997T2 (es)
DK (1) DK1070065T3 (es)
DZ (1) DZ2756A1 (es)
EA (1) EA003400B1 (es)
ES (1) ES2204154T3 (es)
HK (1) HK1035719A1 (es)
HR (1) HRP20000653A2 (es)
HU (1) HUP0102400A3 (es)
ID (1) ID26086A (es)
IL (1) IL138629A0 (es)
IS (1) IS5641A (es)
MA (1) MA26619A1 (es)
MY (1) MY133390A (es)
NO (1) NO20005004L (es)
NZ (1) NZ507010A (es)
OA (1) OA11496A (es)
PA (1) PA8469101A1 (es)
PE (1) PE20000413A1 (es)
PL (1) PL343408A1 (es)
PT (1) PT1070065E (es)
SK (1) SK14782000A3 (es)
TN (1) TNSN99056A1 (es)
TR (1) TR200002932T2 (es)
TW (1) TW555758B (es)
WO (1) WO1999052907A1 (es)
YU (1) YU59400A (es)
ZA (1) ZA992596B (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6231833B1 (en) 1999-08-05 2001-05-15 Pfizer Inc 2,7-substituted octahydro-1H-pyrido[1,2-A]pyrazine derivatives as ligands for serotonin receptors
UA62015C2 (en) 1998-12-28 2003-12-15 Pfizer Prod Inc Benzoizoxazol derivatives, a pharmaceutical composition (variants) based thereon (variants) and a method for treatment (variants)
EE05315B1 (et) * 1999-09-03 2010-08-16 Eli Lilly And Company Dapoksetiini v?i selle farmatseutiliselt vastuv?etava soola kasutamine ravimi valmistamiseks, mis on ette n„htud imetajal esineva seksuaalse funktsioonih„ire ravimiseks v?i m?jutamiseks
GB2362826A (en) * 2000-06-02 2001-12-05 Lilly Co Eli A pharmaceutical composition comprising a serotonin transport inhibitor and a serotonin recptor antagonist
US6855729B2 (en) * 2001-02-20 2005-02-15 Timothy G. Dinan Treatment of fibromyalgia and related fatigue syndromes using antagonists or partial agonists of 5HT1a receptors
PL378749A1 (pl) * 2003-03-12 2006-05-15 Pfizer Products Inc. Azabicykliczne pochodne pirydyloksymetylowe i benzoizoksazolowe
MXPA06008647A (es) * 2004-01-29 2006-09-04 Pfizer Prod Inc Combinaciones de un antipsicotico atipico y derivados azabiciclicos aminometilpiridiloximetil/bencisoxazol para tratar trastornos del sistema nervioso central.
JP4559749B2 (ja) * 2004-02-16 2010-10-13 あすか製薬株式会社 ピペラジニルピリジン誘導体
AR048112A1 (es) 2004-03-25 2006-03-29 Solvay Pharm Bv Derivados de 1-(2h-1-benzopiran-2-on-8-il)-piperazina para el tratamiento de dolor
AR049478A1 (es) 2004-03-25 2006-08-09 Solvay Pharm Bv Un procedimiento para la preparacion de 3-amino-8-(1-piperazinil)-2h-1-benzopiran-2-ona. sales e hidratos y composiciones farmaceuticas.
JP2008503560A (ja) * 2004-06-22 2008-02-07 ファイザー・プロダクツ・インク ジアザビシクロ系のヒスタミン−３受容体アンタゴニスト
EP2400300A1 (en) 2004-08-25 2011-12-28 Takeda Pharmaceutical Company Limited Method of screening preventives/remedies for stress urinary incontinence
WO2006027692A2 (en) * 2004-09-10 2006-03-16 Pfizer Products Inc. Methods of treating cognitive disorders using pyridyloxymethyl and benzisoxazole azabicyclic derivatives
JP6440625B2 (ja) 2012-11-14 2018-12-19 ザ・ジョンズ・ホプキンス・ユニバーシティー 精神分裂病を処置するための方法および組成物
WO2020183011A1 (en) 2019-03-14 2020-09-17 Institut Curie Htr1d inhibitors and uses thereof in the treatment of cancer

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5106849A (en) * 1988-05-24 1992-04-21 American Home Products Corporation Use of aryl- and heteroaryl piperazinyl carboxamides in the treatment of various central nervous system disorders
WO1990008148A1 (en) * 1989-01-23 1990-07-26 Pfizer Inc. Bis-aza-bicyclic anxiolytic agents
US5157034A (en) 1991-02-27 1992-10-20 Pfizer Inc. Neuroleptic perhydro-1H-pyrido[1,2-a]pyrazines
ES2096099T3 (es) * 1991-09-25 1997-03-01 Pfizer Perhidro-1h-pirido(1,2,a)pirazinas 2-sustituidas neurolepticas.
US5262428A (en) * 1992-03-13 1993-11-16 Wake Forest University Biologically active tropane derivatives
CA2138018C (en) * 1992-06-16 1998-01-27 Frank J. Urban Process and intermediates for bis-aza-bicyclic anxiolytic agents
GB9410512D0 (en) * 1994-05-25 1994-07-13 Smithkline Beecham Plc Novel treatment
WO1996010570A1 (en) * 1994-09-30 1996-04-11 Pfizer Inc. NEUROLEPTIC 2,7-DISUBSTITUTED PERHYDRO-1H-PYRIDO[1,2-a]PYRAZINES
US5614523A (en) * 1995-01-17 1997-03-25 Eli Lilly And Company Compounds having effects on serotonin-related systems

Also Published As

Publication number Publication date
ATE248838T1 (de) 2003-09-15
KR100378931B1 (ko) 2003-04-07
AU749254B2 (en) 2002-06-20
DE69910997D1 (de) 2003-10-09
HUP0102400A2 (hu) 2001-11-28
NZ507010A (en) 2003-05-30
NO20005004D0 (no) 2000-10-04
BG104915A (en) 2001-07-31
JP3496759B2 (ja) 2004-02-16
HK1035719A1 (en) 2001-12-07
TNSN99056A1 (fr) 2005-11-10
CN1117092C (zh) 2003-08-06
HRP20000653A2 (en) 2001-04-30
ES2204154T3 (es) 2004-04-16
AR015751A1 (es) 2001-05-16
YU59400A (sh) 2003-10-31
DE69910997T2 (de) 2004-05-19
NO20005004L (no) 2000-11-27
EP1070065B1 (en) 2003-09-03
MY133390A (en) 2007-11-30
TR200002932T2 (tr) 2001-01-22
AP9901502A0 (en) 1999-06-30
ZA992596B (en) 2000-10-08
AP1175A (en) 2003-06-04
CZ20003684A3 (cs) 2002-03-13
CA2327782A1 (en) 1999-10-21
PE20000413A1 (es) 2000-05-25
PL343408A1 (en) 2001-08-13
MA26619A1 (fr) 2004-12-20
SK14782000A3 (sk) 2002-06-04
KR20010042527A (ko) 2001-05-25
TW555758B (en) 2003-10-01
PT1070065E (pt) 2003-12-31
EA200000910A1 (ru) 2001-04-23
BR9909522A (pt) 2000-12-19
EA003400B1 (ru) 2003-04-24
EP1070065A1 (en) 2001-01-24
IS5641A (is) 2000-09-26
DZ2756A1 (fr) 2003-09-15
US6525048B1 (en) 2003-02-25
IL138629A0 (en) 2001-10-31
ID26086A (id) 2000-11-23
JP2002511469A (ja) 2002-04-16
WO1999052907A1 (en) 1999-10-21
CN1305477A (zh) 2001-07-25
AU3268799A (en) 1999-11-01
DK1070065T3 (da) 2003-11-24
HUP0102400A3 (en) 2002-10-28
CO5080727A1 (es) 2001-09-25
US6887905B2 (en) 2005-05-03
OA11496A (en) 2004-05-14
US20030181458A1 (en) 2003-09-25

Similar Documents

Publication Publication Date Title
ES2178152T3 (es) Nuevas modificaciones de 2-amino-4-(4-fluorobenzilamino)-1-etoxicarbonilaminobenceno y procedimientos para la preparacion de dicho compuesto.
PA8469101A1 (es) Ligandos azabiciclicos de receptores 5ht1
GT199900215A (es) Formulaciones agroquimicas.
GT199900102A (es) Fenoxipropanolaminas, procedimiento para su preparacìon y composiciones farmacèuticasque las contienen.
SV2002000205A (es) Compuestos farmaceuticos ref. x-01095
ES2161085T3 (es) Formulaciones que contienen oxaliplatino.
HN2002000300A (es) Nuevos derivados de piperazina
ES2178298T3 (es) Compuestos anti-inflamatorios.
AR004700A1 (es) 1alfa, 26 dihidroxi-d-homo-vitamina d3, una composicion farmaceutica que la comprende, un procedimiento para su preparacion y el uso de los mismos en laelaboracion de un medicamento
ES2144192T3 (es) Nuevos derivados de 1-fenil-2-dimetil-amino-metil-ciclohexan-1-ol, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen.
GT200600258A (es) Derivados de n-(piridin-2-il)-sulfonamida
PA8435001A1 (es) Derivados 6,6-heterobiciclicos sustituidos.
AR023423A1 (es) Derivados de adamantano, procedimientos para su preparacion, composicion farmaceutica, procedimiento para la preparacion de la composicion farmaceutica, yuso de dichos derivados para la manufactura de medicamentos
ES2170460T3 (es) Compuestos triaromaticos, composiciones que los contienen y utilizaciones.
CR6398A (es) Antagonistas de 5ht1 para terapia antidepresiva
HN2001000235A (es) Derivados puentes de piperazina
ES2143734T3 (es) Compuestos bioaromaticos que llevan un grupo adamantilo en para, composiciones farmaceuticas y cosmeticas que los contienen y utilizaciones.
BR0314195A (pt) Derivados de piridina substituìda como agentes antitumorais
ECSP941120A (es) Derivados de 1,5 benzodiazepina
SV1999000115A (es) Derivados de sulfonamida ref. x-12301
MX9308006A (es) Derivados de 4-benzoilisoxazol, procedimiento para su preparcion y composicion herbicida que los comprende.
ES2147453T3 (es) Antagonistas de adenosina, procedimiento para su preparacion y su uso como medicamentos.
ES2186989T3 (es) Cristales de maltitol de formas especificas, compuestos cristalinos que los contienen y procedimientos para su preparacion.
HN2000000056A (es) Nuevas formas cristalinas de un antibiotico macrolido
ES2184424T3 (es) Nuevos compuestos heteroetinilenos y composiciones farmaceuticas y cosmeticas que los contienen.